<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - BEVACIZUMAB</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>BEVACIZUMAB</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy</span>,
                <span class="indication">First-line treatment of metastatic breast cancer in combination with paclitaxel when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate</span>,
                <span class="indication">First-line treatment of metastatic breast cancer in combination with capecitabine when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate (patients who have received adjuvant taxane or anthracycline-containing regimens in the previous 12 months should not be treated with bevacizumab in combination with capecitabine)</span>,
                <span class="indication">Advanced or metastatic renal cell carcinoma in combination with interferon alfa-2a</span>,
                <span class="indication">First-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology (In combination with platinum-based chemotherapy)</span>,
                <span class="indication">First-line treatment of advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with carboplatin and paclitaxel)</span>,
                <span class="indication">First recurrence of platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have not been treated previously with bevacizumab or other drugs that target vascular endothelial growth factor (in combination with carboplatin and gemcitabine)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult local protocol).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>
            <b>Bevacizumab</b> is a monoclonal antibody that inhibits vascular endothelial growth factor.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid&#8212;toxicity in <i>animal</i> studies.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>
            </section>
      </section>




      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Abdominal pain, alopecia, anaemia, anorexia, arterial thromboembolism, asthenia, bone marrow suppression, chest pain, congestive heart failure, constipation, dehydration, diarrhoea, drowsiness, dry skin, dysarthria, dyspnoea, exfoliative dermatitis, extravasation, eye disorders, fistulas, flushing, gall bladder perforation, gastro-intestinal perforation, haemorrhage, hand-foot syndrome, headache, hypersensitivity reactions, hypertension, hyperuricaemia, hypotension, hypoxia, impaired wound healing, infection, intestinal obstruction, lethargy, mucocutaneous bleeding, nausea, necrotising fasciitis (discontinue and initiate treatment promptly), neutropenia, oral mucositis, osteonecrosis of the jaw, peripheral neuropathy, posterior reversible encephalopathy syndrome, proteinuria, pulmonary hypertension, pyrexia, rash, rhinitis, rigors, skin discoloration, supraventricular tachycardia, syncope, taste disturbances, thrombocytopenia, thromboembolism, tumour lysis syndrome, vomiting,
              </p>
        
        
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA118</h3>
              <p outputclass="title">Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007)</p> <p>Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is <b>not</b> recommended for the first-line treatment of metastatic colorectal cancer; see also NICE guidance Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy.</p><xref format="html" href="http://www.nice.org.uk/TA118">www.nice.org.uk/TA118</xref>
                <a href="http://www.nice.org.uk/TA118" target="_blank">www.nice.org.uk/TA118</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA178</h3>
              <p outputclass="title">Bevacizumab (first-line), sorafenib (firstand second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) </p> <p>Bevacizumab, sorafenib, and temsirolimus are <b>not</b> recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma. Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.</p><xref format="html" href="http://www.nice.org.uk/TA178">www.nice.org.uk/TA178</xref>
                <a href="http://www.nice.org.uk/TA178" target="_blank">www.nice.org.uk/TA178</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA212</h3>
              <p outputclass="title">Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</p> <p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is <b>not</b> recommended for the treatment of metastatic colorectal cancer.</p><xref format="html" href="http://www.nice.org.uk/TA212">www.nice.org.uk/TA212</xref>
                <a href="http://www.nice.org.uk/TA212" target="_blank">www.nice.org.uk/TA212</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA214</h3>
              <p outputclass="title">Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011)</p> <p>Bevacizumab in combination with a taxane is <b>not</b> recommended for the first-line treatment of metastatic breast cancer.</p><xref format="html" href="http://www.nice.org.uk/TA214">www.nice.org.uk/TA214</xref>
                <a href="http://www.nice.org.uk/TA214" target="_blank">www.nice.org.uk/TA214</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA242</h3>
              <p outputclass="title">Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012)</p> <p>Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy is <b>not</b> recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy; see also NICE guidance Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007).</p><xref format="html" href="http://www.nice.org.uk/TA242">www.nice.org.uk/TA242</xref>
                <a href="http://www.nice.org.uk/TA242" target="_blank">www.nice.org.uk/TA242</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA263</h3>
              <p outputclass="title">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012)</p> <p>Bevacizumab in combinations with capecitabine is <b>not</b> recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.</p><xref format="html" href="http://www.nice.org.uk/TA263">www.nice.org.uk/TA263</xref>
                <a href="http://www.nice.org.uk/TA263" target="_blank">www.nice.org.uk/TA263</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA284</h3>
              <p outputclass="title">Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer (May 2013)</p> <p>Bevacizumab in combination with paclitaxel and carboplatin is <b>not</b> recommended for the first-line treatment of advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).</p><xref format="html" href="http://www.nice.org.uk/TA284">www.nice.org.uk/TA284</xref>
                <a href="http://www.nice.org.uk/TA284" target="_blank">www.nice.org.uk/TA284</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA285</h3>
              <p outputclass="title">Bevacizumab in combination with gemcitabine and carboplatin for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013)</p> <p>Bevacizumab in combination with gemcitabine and carboplatin is <b>not</b> recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.</p><xref format="html" href="http://www.nice.org/TA285">www.nice.org/TA285</xref>
                <a href="http://www.nice.org/TA285" target="_blank">www.nice.org/TA285</a>
            </section>
      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>MHRA/CHM advice: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)</h3>
              <p>Treatment with bevacizumab or sunitinib may be a risk factor for the development of osteonecrosis of the jaw.</p><p>Patients treated with bevacizumab or sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.</p><p>Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.</p><p>If possible, invasive dental procedures should be avoided in patients treated with bevacizumab or sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Elective surgery (withhold treatment and avoid for at least 28 days after major surgery or until wound fully healed)
          </li>
          <li>
            history of arterial thromboembolism
          </li>
          <li>
            history of cardiovascular disease (increased risk of cardiovascular events, especially in the elderly)
          </li>
          <li>
            history of hypertension (increased risk of proteinuria&#8212;discontinue if nephrotic syndrome)
          </li>
          <li>
            increased risk of fistulas (discontinue permanently if tracheo-oesophageal or grade 4 fistula develops)
          </li>
          <li>
            increased risk of haemorrhage
          </li>
          <li>
            increased risk of tumour-associated haemorrhage
          </li>
          <li>
            intra-abdominal inflammation (risk of gastro-intestinal perforation and gall bladder perforation
          </li>
          <li>
            uncontrolled hypertension
          </li>
          <li>
            untreated CNS metastases
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to before cytotoxic therapy begins&#8212;effective contraception required during and for at least 6 months after treatment in women.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor for necrotising fasciitis (usually secondary to wound healing complications, gastro-intestinal perforation or fistula formation)&#8212;discontinue and initiate treatment promptly.</p><p>Monitor blood pressure.</p><p>Monitor for congestive heart failure.</p><p>Monitor for posterior reversible encephalopathy syndrome (presenting as seizures, headache, altered mental status, visual disturbance or cortical blindness, with or without hypertension).</p><p>Consider dental check-up before initiating treatment (risk of osteonecrosis of the jaw).</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of BEVACIZUMAB</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for injection,

            <div id="PHP75890"><a href="../medicinalForm/PHP75890.html" data-target="#PHP75890" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
